Published in Medical Letter on the CDC and FDA, June 8th, 2008
The FDA approved Treximet for the acute treatment of migraine attacks, with or without aura, in adults on April 15, 2008. Treximet will be commercialized by GlaxoSmithKline.
Keywords: Biotechnology, Drug Development, Drugs, GlaxoSmithKline, Naproxen Sodium, Pharmaceutical Business, Pharmaceutical Company, Pharmaceuticals, Regulatory Actions, Selective Serotonin Agonist, Sumatriptan, Therapy,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA